The HIVACAT T-cell immunogen (HTI) is a novel human immunodeficiency virus (HIV) vaccine immunogen designed to elicit cellular immune responses against the HIV targets associated with viral control in the human body.recently, One was published in the international magazine Nature Medicine, titled " Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial " reported, Scientists from Oxford University and other institutions, by conducting a phase I / Iia clinical trial, the results show that, When antiretroviral therapy (ART) is temporarily stopped, The T cell-therapeutic HIV vaccine may be related to better control of the virus rebound.
By conducting the AELIX-002 study, the investigators reported that two out of five participants could not receive ART therapy without any genetic background associated with spontaneous HIV control. In this paper, the vaccine developed by AELIX uses a combination of a DNA vector, an improved vaccine virus Ankara (MVA) vector, and a simulated adenovirus vector, ChAdOx1, to provide HIVACAT T cell immunogens.
Investigator Tomas Hanke said the findings could make the body's active immunity to HIV possible, could also slow down HIV replication and provide a holiday treatment window for HIV patients, leading to a cure for HIV. T-cell / T-cell vaccines are likely to play an important role in the final cure for HIV, and, perhaps, in other advanced therapies for difficult diseases. The investigators noted that the participants received multiple rounds of vaccination and were monitored weekly for the body's viral load before the ART interruption.
Of the 45 participants recruited to the study, 41 reached the treatment interruption phase, 26 received vaccination, 15 received placebo under a double-blind trial design, and neither the patient nor the investigators understood how the patient was assigned until the study ended. In those populations without a protective genotype, eight vaccinees were treated off of ART, and all but one placebo participant had to resume treatment before the end of the 6-month treatment break.
Investigator Hanke directed an HIV vaccine program at the Jenner Institute to develop new vaccine strategies to induce protective T cells for targeted HIV susceptibility areas, while researchers have also conducted trials in the UK, Europe, the United States and Africa. In conclusion, despite the limited efficacy of vaccines in preventing viral rebound, the powerful T cell response induced against HIVACAT T cell immunogens may be beneficial for combination cure strategies, and the researchers will continue to conduct relevant clinical trials.
